Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198–203. doi: 10.1097/WAD.0b013e3181c53b00

TABLE 3.

Summary of Pharmacokinetic Parameters (Serum) of Bapineuzumab

Bapineuzumab Variables Cmax (μg/mL) tmax* (h) AUC (μg×h/mL) t½ (d) Cl (mL/h/kg) Vss (mL/kg) MRT (d)
0.5 mg/kg Mean ± SD 7.51 ± 1.41 1.75 (0.95–2.00) 2716 ± 462 24.0 ± 4.0 0.190 ± 0.040 147 ± 27.4 32.8 ± 7.54
n = 6 % CV 18.8 17 16.7 21.1 18.6 23.0
1.5 mg/kg Mean ± SD 45.7 ± 6.59 1.53 (1.00–6.00) 15,890 ± 3950 21.0 ± 1.53 0.099 ± 0.023 69.7 ± 10.1 30.2 ± 6.13
n = 6 % CV 14.4 24.9 7.3 23.0 14.4 20.3
5 mg/kg Mean ± SD 114 ± 29.9 1.31 (0.50–6.00) 38,993 ± 5008 26.1 ± 4.96 0.130 ± 0.016 116 ± 17.1 33.8 ± 6.75
n = 10 % CV 26.1 12.8 19.0 12.2 14.7 20.0
*

Median and range are provided for tmax.

AUC indicates area under the concentration-versus-time curve; Cl, systemic clearance; Cmax, peak concentration; CV, coefficient of variation; MRT, mean residence time; SD, standard deviation; t½, terminal phase elimination half-life; tmax, time to peak concentration; Vss, apparent steady-state volume of distribution.

HHS Vulnerability Disclosure